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Despite excellent vaccine coverage in developed countries, whooping cough is a reemerging disease that can 
be caused by two closely related pathogens, Bordetella pertussis and B. parapertussis. The two are antigenically 
distinct, and current vaccines, containing only B. pertussis-derived antigens, confer efficient protection against 
B. pertussis but not against B. parapertussis. B. pertussis does not express the O antigen, while B. parapertussis 
retains it as a dominant surface antigen. Since the O antigen is a protective antigen for many pathogenic 
bacteria, we examined whether this factor is a potential protective antigen for B. parapertussis. In a mouse 
model of infection, immunization with wild-type B. parapertussis elicited a strong antibody response to the O 
antigen and conferred efficient protection against a subsequent B. parapertussis challenge. However, immuni­
zation with an isogenic mutant lacking the O antigen, B. parapertussis Swbm, induced antibodies that recog­
nized other antigens but did not efficiently mediate opsonophagocytosis of B. parapertussis. The passive transfer 
of sera raised against B. parapertussis, but not B. parapertussis Swbm, reduced B. parapertussis loads in the lower 
respiratory tracts of mice. The addition of 10 pig of purified B. parapertussis lipopolysaccharide (LPS), which 
contains the O antigen, but not B. parapertussis Swbm LPS drastically improved the efficacy of the acellular 
vaccine Adacel against B. parapertussis. These data suggest that the O antigen is a critical protective antigen 
of B. parapertussis and its inclusion can substantially improve whooping cough vaccine efficacy against this 
pathogen.
Bordetella pertussis and B. parapertussis are the causative 
agents of whooping cough, resulting in approximately 50 mil­
lion cases and 300,000 deaths annually worldwide (28). While 
whooping cough is considered by the CDC to be a reemerging 
disease (5), the relative incidences of B. pertussis and B. para­
pertussis are not clear (50). It is known, however, that the 
resurgence of whooping cough roughly correlates with the in­
troduction of acellular pertussis vaccines (5). These vaccines 
contain only B. pertussis-derived antigens and confer little to no 
protection against B. parapertussis (9, 14, 15, 23, 27, 28). Cur­
rent acellular pertussis vaccines contain some combination of 
filamentous hemagglutinin, pertactin, and fimbriae 2 and 3, all 
of which are expressed by both B. pertussis and B. parapertussis, 
and pertussis toxin, which is 7>. pertussis specific (33, 34). Based 
on genome sequences, the levels of amino acid sequence 
identity between B. pertussis and B. parapertussis filamentous 
hemagglutinin, pertactin, and fimbria 2 and 3 proteins are 
about 98, 91, 71, and 92% (35), and antibodies raised against 
these antigens from B. pertussis cross-react with B. paraper­
tussis (17, 31). However, immunization with purified B. per­
tussis filamentous hemagglutinin or pertactin does not con­
fer protection against B. parapertussis (17). B. pertussis 
fimbriae confer some protection against B. parapertussis, but 
at much lower levels than they protect against B. pertussis 
(52). Based on these observations and the fact that B. para­
pertussis infection induces protective immunity to itself (56, 58), 
we hypothesized that the lack of protective antigens from B. 
parapertussis may be part of the reason why current whooping 
cough vaccines are ineffective against this bacterium.
Although B. pertussis and B. parapertussis are very closely 
related (8, 35, 48), they differ in the structure of their lipopoly­
saccharides (LPS) (1, 2, 39, 40, 47). B. pertussis produces a 
lipooligosaccharide containing lipid A and a branched-chain 
core oligosaccharide with a complex trisaccharide modification 
but lacks the O antigen due to a natural deletion of the wbm 
locus responsible for its synthesis (39, 47). B. parapertussis LPS 
is similar to B. pertussis LPS but lacks the trisaccharide modi­
fication and includes an O antigen (39, 40). In addition to 
conferring serum resistance by inhibiting C3 deposition onto the 
surfaces of bacteria (11), the O antigen enables B. parapertussis to 
avoid B. pertussis-induced immunity by preventing antibody bind­
ing to cross-reactive antigens on the surfaces of B. parapertussis 
cells (56,59 ). Since the O antigen is one dominant surface antigen 
recognized by B. parapertussis immune sera (56) and has been 
shown previously to be a protective antigen of various pathogenic 
bacteria (22, 36), we hypothesized that the O antigen is a protec­
tive antigen of B. parapertussis.
To assess the role of the O antigen in the generation of an 
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adaptive immune response to B. parapertussis, the immunity 
and protection generated by B. parapertussis infection or vac­
cination were compared to those generated by an isogenic 
mutant of B. parapertussis lacking the O antigen (Swbm) (39). 
Animals immunized with B. parapertussis, but not B. paraper­
tussis Swbm, were protected against subsequent challenge with 
B. parapertussis. Mice immunized with B. parapertussis Swbm 
were also deficient in the production of B. parapertussis-specific 
antibodies, and sera collected from these mice were less effec­
tive at reducing B. parapertussis colonization upon passive 
transfer than sera raised against B. parapertussis. The inclusion 
of LPS from B. parapertussis, but not from B. parapertussis 
Swbm, rendered the acellular B. pertussis vaccine Adacel effi­
cacious against B. parapertussis challenge. Together, these data 
indicate that the O antigen is an important protective antigen 
of B. parapertussis.
MATERIALS AND METHODS
Bacterial strains and growth. B. pertussis strain 536, B. parapertussis strain 
CN2591, and the isogenic B. parapertussis mutant strain lacking the O antigen, 
CN2591 Lwbm, have been described previously (39, 46). For opsonization, at­
tachment, and phagocytosis experiments, these strains were transformed with 
plasmid pCW505 (kindly supplied by Alison Weiss, Cincinnati, OH), which 
induces cytoplasmic expression of green fluorescent protein (GFP) without af­
fecting growth or antigen expression (51). Bacteria were maintained on Bordet- 
Gengou agar (Difco) supplemented with 10% sheep blood (Hema Resources) 
and 20 pg/ml streptomycin (Sigma-Aldrich). Liquid cultures were grown over­
night on a roller drum at 37°C to mid-log phase in Stainer-Scholte broth (44,49).
Cells. Peripheral blood polymorphonuclear leukocytes (PMNs) were isolated 
from heparinized venous blood by using Ficoll-Histopaque (Sigma, St. Louis, 
MO) gradient centrifugation. PMNs were harvested, and the remaining eryth­
rocytes were removed by hypotonic lysis. Cell viability was >99% as determined 
by trypan blue exclusion. Prior to functional assays, PMNs were washed twice 
with Dulbecco’s modified Eagle medium (HyClone) supplemented with 10% 
fetal calf serum (HyClone) and resuspended, and the cells were used immedi­
ately. All experiments were carried out with freshly isolated PMNs lacking FcyRI 
(CD64) expression, as monitored by fluorescence-activated cell sorter analysis 
using a FACScan flow cytometer (Becton Dickinson, San Jose, CA) with anti- 
FcyRI monoclonal antibody 22 (41).
Opsonization. GFP-expressing strains were opsonized by incubation at 37°C 
for 30 min in a final volume of 50 pl containing 5% heat-inactivated serum 
samples from naive C3_/_ mice or convalescent C3_/_ mice challenged with 
CN2591 or CN2591 Lwbm. Serum-opsonized bacteria were incubated with R- 
phycoerythrin (RPE)-labeled goat F(ab')2 fragments of anti-mouse immuno­
globulin G (IgG; Southern Biotechnology, Birmingham, AL) for 30 min at 4°C. 
The opsonization of each strain was assessed by fluorescence-activated cell sorter 
analysis (43).
Attachment and phagocytosis. Attachment and phagocytosis of the B. para­
pertussis strains were evaluated as described previously, with a few modifications 
(42). Briefly, serum-opsonized, GFP-expressing bacteria were subsequently in­
cubated with PMNs at a multiplicity of infection of 30 for 20 min at 37°C to allow 
binding. In selected experiments, 200 ng/ml cytochalasin D (Sigma-Aldrich) was 
added to inhibit phagocytosis. After extensive washing to remove unattached 
bacteria, an aliquot was maintained on ice to be used as a bacterial attachment 
control. Another aliquot was further incubated for 1 h at 37°C to allow inter­
nalization. Phagocytosis was stopped by placing PMNs on ice. Cell surface-bound 
bacteria in both aliquots (obtained before and after 1 h of incubation at 37°C) 
were detected by incubation with RPE-labeled goat F(ab')2 fragments of anti­
mouse IgG at 4°C for 30 min. To avoid eventual cytophilic binding of antibodies, 
all incubations were done in the presence of 25% heat-inactivated human serum. 
After being washed, samples were analyzed by flow cytometry. Ten thousand 
cells per sample were analyzed. Green fluorescence intensity associated with 
PMNs maintained at 37°C for 20 min was determined to indicate the level of 
bacterial attachment. The decrease in red fluorescence after incubation for 1 h at 
37°C reflects bacterial phagocytosis. Phagocytosis was calculated from the drop 
in the mean red fluorescence intensity of green fluorescence-positive cells as 
described previously (42).
Animal experiments. C57BL/6 mice were obtained from Jackson Laboratories. 
C3_/_ mice were kind gifts from Rick Wetsel and have been described elsewhere 
(7). All mice were bred in our Bordetella-ixcc, specific-pathogen-free breeding 
rooms at The Pennsylvania State University. Four- to six-week-old mice were 
sedated with 5% isoflurane (Abbott Laboratory) in oxygen and inoculated by 
pipetting of 50 pl of phosphate-buffered saline (PBS; Omnipur) containing 5 X 
105 CFU of bacteria onto the external nares (18). This method reliably distrib­
utes the bacteria throughout the respiratory tract (13). For rechallenge experi­
ments, mice were treated with gentamicin in drinking water (10 mg/ml) for 7 days 
starting on day 21 postinoculation (57). Mice were challenged with 5 X 105 CFU 
of bacteria on day 30 postinoculation and dissected 3 days postchallenge (57). 
For passive transfer of sera, 200-pl serum samples (collected on day 28 post in­
oculation) from naive or convalescent C3_/_ mice were intraperitoneally (i.p.) 
injected at the time of inoculation (19, 38). For vaccination, mice were i.p. 
injected with 108 CFU of heat-killed CN2591 or CN2591 Lwbm in 200 pl of PBS 
with Imject Alum adjuvant (Pierce) on days 0 and 14. For acellular B. pertussis 
vaccinations, mice were i.p. injected with one-fifth of a human dose of Adacel 
(Sanofi Pasteur; 0.5 pg of pertussis toxin, 1 pg of filamentous hemagglutinin, 0.6 
pg of pertactin, and a 5-pg mixture of fimbriae 2 and 3 per mouse) in a 200-pl 
volume containing PBS and Imject Alum adjuvant with or without 10 pg of 
purified CN2591 LPS or CN2591 Lwbm LPS (45) on days 0 and 14. Vaccinated 
mice were challenged with bacteria on day 28. Mice were sacrificed via CO2 
inhalation, and the lungs, tracheae, and nasal cavities were excised. Tissues were 
homogenized in PBS, serially diluted, and plated onto Bordet-Gengou agar, and 
colonies were counted after incubation at 37°C for 3 to 4 days (25). All protocols 
were reviewed and approved by The Pennsylvania State University Institutional 
Animal Care and Use Committee, and all animals were handled in accordance 
with institutional guidelines.
Splenocyte restimulations. Spleens were taken from C57BL/6 mice immunized 
with CN2591 or CN2591 Lwbm on day 28 postinoculation. Splenocytes were isolated 
as described previously (25, 37). In brief, spleens were homogenized and red blood 
cells were lysed by 0.84% ammonium chloride treatment. Aliquots of cells (2 X 106) 
were resuspended in Dulbecco’s modified Eagle medium supplemented with 10% 
fetal calf serum, 1 mM sodium pyruvate (HyClone), and 100 pg/ml penicillin­
streptomycin (HyClone) and placed into each well of a 96-well tissue culture plate. 
Splenocytes were stimulated with either medium alone or medium containing 107 
CFU of heat-killed CN2591 or CN2591 Lwbm (multiplicity of infection of 5) (37). 
After 3 days, the supernatants were collected and analyzed for gamma interferon 
(IFN-y) and interleukin-10 (IL-10) production via enzyme-linked immunosorbent 
assays (ELISAs) per the instructions of the manufacturer (R&D Systems).
Titer ELISAs. Antibody titers were determined as described previously (25, 
56). In brief, exponential-phase live CN2591 or CN2591 Lwbm bacteria were 
diluted to 5 X 107 CFU/ml in a 1:1 mix of 0.2 M sodium carbonate and 0.2 M 
sodium bicarbonate buffers. The wells of 96-well plates were coated with these 
antigens, and the plates were incubated for 2 h at 37°C in a humidified chamber 
and then washed and blocked. Serum samples from individual mice were diluted 
1:50, added to the first wells of the plates, and serially diluted 1:2 across the 
plates, and the plates were incubated for 2 h at 37°C. Plates were washed, probed 
with a 1:4,000 dilution of goat anti-mouse Ig horseradish peroxidase-conjugated 
antibodies (Southern Biotech) for 1 h, and washed again prior to visualization 
with 2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt in 
phosphate-citrate buffer with hydrogen peroxide at an absorbance of 405 nm. 
Titers were determined via the end point method based on optical densities in 
identically treated wells probed with naive sera.
Western blot analysis. Lysates containing 107 CFU of heat-killed CN2591 or 
CN2591 Lwbm were run on 10% sodium dodecyl sulfate-poly acrylamide gel 
electrophoresis gels under denaturing conditions. Polyvinylidene difluoride 
membranes (Millipore) were probed overnight with either naive sera or sera 
from CN2591- or CN2591 Awbm-inoculated mice at a 1:500 dilution. Goat 
anti-mouse Ig horseradish peroxidase-conjugated antibodies (Southern Biotech) 
were used at a dilution of 1:10,000 as the detector antibody (56, 57). The 
membrane was visualized with enhanced chemiluminescence Western blotting 
detection reagent (Pierce Biotechnology).
Statistical analysis. The mean ± standard error was determined for all ap­
propriate data. Two-tailed, unpaired Student’s t tests were used to determine the 
statistical significance of differences between groups. All experiments were per­
formed at least twice with similar results.
RESULTS
The O antigen is required for efficient generation of protec­
tive immunity against B. parapertussis infection. To determine
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FIG. 1. The O antigen contributes to the generation of protective 
immunity to B. parapertussis. Groups of four C57BL/6 mice were in­
oculated with B. parapertussis (Bpp) or B. parapertussis ¿swbm 
(BppLwbm') and allowed to convalesce. Naive and immunized mice 
were challenged with the indicated bacteria. The numbers of CFU 
recovered from the nasal cavities, tracheae, and lungs at day 3 post­
challenge are expressed as the log10 means ± the standard errors. * 
indicates a P value of <0.05 for comparison to results for naive mice; 
H indicates a P value of <0.01. The limit of detection is indicated by 
the y axis.
whether the O antigen contributes to the generation of B. 
parapertussis infection-induced protective immunity against 
secondary challenge, mice were intranasally inoculated with 
either B. parapertussis or B. parapertussis Awhm and challenged 
with either B. parapertussis or B. parapertussis Awhm. Naive 
animals challenged with wild-type B. parapertussis had mean 
loads of 106,2, 1()61, and 106,7 CFU in the nasal cavity, trachea, 
and lungs on day 3 postchallenge (Fig. 1, black bars). Mice 
previously inoculated with B. parapertussis were substantially 
immune to subsequent challenge, harboring approximately 103 
CFU in the nasal cavity, and had cleared the bacteria from 
both the trachea and lungs by 3 days postchallenge (Fig. 1, 
white bars). Prior infection with B. parapertussis and B. para­
pertussis ¿Swbm conferred similar levels of protection in the 
lower respiratory tract (LRT) against subsequent B. paraper­
tussis ¿Swbm challenge (Fig. 1, right). Interestingly, B. paraper­
tussis infection induced more protection against the O-antigen- 
deficient strain in the nasal cavity than B. parapertussis Awbm 
infection did (Fig. 1, top right). However, mice immunized 
with B. parapertussis Awbm harbored at least 8,000-fold more 
B. parapertussis bacteria in the lungs, 104,9 CFU, than B. para- 
pemm/.s-immiiiiized mice (P < 0.01) (Fig. 1, bottom), indicat-
FIG. 2. A response against the O antigen contributes to effective 
vaccine-induced immunity. Groups of four C57BL/6 mice were vacci­
nated with adjuvant only, B. parapertussis with adjuvant (Bpp), or B. 
parapertussis ¿swbm with adjuvant (Bpp&wbm) and challenged with B. 
parapertussis. The numbers of CFU recovered from the nasal cavities, 
tracheae, and lungs at day 3 postchallenge are expressed as the log10 
means ± the standard errors. * indicates a P value of <0.05 for 
comparison to results for mice vaccinated with adjuvant only; indi­
cates a P value of <0.01. The limit of detection is indicated by the y 
axis.
ing that the mutant lacking the O antigen did not induce 
effective protective immunity.
Effective vaccine-induced immunity requires a response 
against the O antigen. B. parapertussis ¿Swbm is known to 
colonize at a lower level than B. parapertussis in the presence of 
complement (11), raising the possibility that its defect in col­
onization contributes to the decreased protection against sub­
sequent challenge (Fig. 1). To deliver equivalent amounts of 
antigens, mice were vaccinated with heat-killed B. parapertussis 
or B. parapertussis Awbm. Sham-vaccinated control mice chal­
lenged with B. parapertussis harbored 106'4, 1 ()5 K, and 1()6K 
CFU in the nasal cavity, trachea, and lungs 3 days later (Fig. 2, 
black bars). Vaccination with B. parapertussis effectively de­
creased B. parapertussis numbers by 99.99% in the LRT and by 
80% in the nasal cavity (Fig. 2, white bars). Although vaccina­
tion with B. parapertussis Awbm reduced B. parapertussis num­
bers in the LRT (Fig. 2, striped bars), animals vaccinated with 
B. parapertussis Awbm had 160-, 16-, and 3-fold more bacteria 
in the lungs, trachea, and nasal cavity than B. parapertussis- 
vaccinated animals (Fig. 2). This decreased protection con­
ferred by B. parapertussis Awbm vaccination further strength­
ens the conclusion that the O antigen is required for the 
efficient generation of an adaptive immune response against B. 
parapertussis.
The O antigen is not required for the development of splenic 
IFN-y and IL-10 responses to B. parapertussis. Since the O 
antigen contributes to the generation of efficient protective 
immunity against B. parapertussis, we investigated whether the 
O antigen is involved in the generation of a T-cell response. 
Splenocytes from naive or B. parapertussis- or B. parapertussis 
Aw/wz-vaccinated mice were stimulated with medium alone or 
with heat-killed B. parapertussis or B. parapertussis Xwbm. and 
3 days later, IFN-y and IL-10 concentrations in the culture 
supernatants were measured. Vaccination with either strain 
resulted in increased IlN-y and IL-10 production. There was 
no significant difference in IFN-y or IL-10 production in re­
sponse to B. parapertussis or B. parapertussis Awbm between 
mice vaccinated with B. parapertussis and those vaccinated with
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splenic IFN-7 or IL-10 responses to B. parapertussis. Splenocytes from 
groups of four C57BL/6 mice vaccinated with adjuvant only, B. para­
pertussis with adjuvant (Bpp Vac), or B. parapertussis Swbm with ad­
juvant (BppSwbm Vac) were stimulated with the indicated bacteria, 
and the resulting IFN-y and IL-10 production levels are expressed as 
mean concentrations ± standard errors. * indicates a P value of £0.05 
for comparison to results for medium-stimulated groups. B.p.p.. wild­
type B. parapertussis', B.p.p.&wbm, B. parapertussis Swbm.
B. parapertussis ¿Swbm (Fig. 3). Since the splenic IFN-y and 
IL-10 responses are T-cell dependent (D. N. Wolfe, M. J. 
Kennett, S. E. Hester, and E. T. Harvill, unpublished data), 
these data suggest that the O antigen is not required for the 
generation of a T-cell response to B. parapertussis.
The O antigen is required for the generation of an efficient 
antibody response against B. parapertussis. As the O antigen is 
required for the generation of anamnestic immunity to B. 
parapertussis but not an efficient T-cell response, we assessed 
whether the O antigen contributes to efficient antibody gener­
ation. In ELISAs using either strain as the antigen, B. para­
pertussis immune serum had significantly less recognition of the 
O antigen mutant than of wild-type bacteria (Fig. 4A, left). B. 
parapertussis \wbm immunization sera had similar Ig titers 
when probed with the wild-type and O antigen mutant B. 
parapertussis strains (Fig. 4A, right). Sera raised against B. 
parapertussis àwbm showed a 44% reduction in B. parapertus- 
s/.s-speci lie antibody titers compared to those in sera raised 
against B. parapertussis (Fig. 4A, first and third bars). These 
data suggest that vaccination with B. parapertussis induces a 
robust antibody response against the O antigen and that vac­
cination with B. parapertussis àwbm induces an antibody re­
sponse to other antigens that are shared.
To compare the antigens recognized by sera from different 
groups, Western blotting analyses were performed with lysates 
of B. parapertussis and B. parapertussis àwbm probed with naïve 
sera or B. parapertussis or B. parapertussis bwbm immune sera 
(Fig. 4B). Naïve sera appeared to minimally bind antigens from 
either lysate (Fig. 4B, lanes 1 and 2). B. parapertussis-induced 
serum antibodies recognized a broad band or smear, band i, 
present in B. parapertussis lysate but not in B. parapertussis 
iswbm lysate (Fig. 4B, lanes 3 and 4), suggesting that it repre­
sents LPS containing the O antigen and that the O antigen is 
one of the dominant antigens of B. parapertussis. Several high­
er-molecular-mass antigens shared by the two strains, for 
example, those represented by bands iii and iv, were also rec­
ognized by B. parapertussis immune serum antibodies. Inter­
estingly, although B. parapertussis AwZwt-induced serum anti­
bodies showed recognition of antigen(s) in band iii, these 
antibodies lacked recognition of antigen(s) in band iv and had 
strong recognition of additional antigen(s) in bands ii and v, 
not recognized by B. parapertussis-induced serum antibodies. 
As expected, the O antigen (band i) was not recognized by B. 
parapertussis iswbm-induced serum antibodies. Together, these 
FIG. 4. The O antigen contributes to the production of a robust anti-B. parapertussis antibody response. (A) Ig titers in sera from groups of four 
C57BL/6 mice immunized with B. parapertussis (B. parapertussis immune sera [B.p.p. IS]) or B. parapertussis iswbm (B.p.p.&wbm IS) supplemented 
with adjuvant were determined via B. parapertussis (B.p.p.)- or B. parapertussis tswbm (B.p.p. tswbm)-specific ELISAs. Titers are expressed as 
means ± standard errors. * indicates a P value of £0.05. (B) Lysates (107 CFU) from B. parapertussis (B.p.p.) or B. parapertussis tSwbm 
(B.p.p.&wbm) were probed with naive sera (NS), sera from B. parapertussis-immunized mice (B.p.p. IS), or sera from B. parapertussis ¿Swbm- 
immunized mice (B.p.p.iswbm IS), as indicated. Roman numerals to the right of the gel identify bands.
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data indicate that immunization with B. parapertussis induces a 
measurably stronger antibody response, dominated by the O 
antigen, than that induced by B. parapertussis Xwbm and that 
immunization with B. parapertussis Xwbm induces a different 
antigen recognition profile from that induced by immunization 
with the wild-type counterpart.
The O antigen contributes to the generation of antibodies 
that mediate opsonophagocytosis of B. parapertussis by PMNs. 
To determine whether antibodies against the O antigen are 
important for some key antibody functions, we assessed the 
opsonization of bacteria and subsequent attachment to, and 
phagocytosis by, PMNs mediated by antibodies raised against 
wild-type or O-antigen-deficient B. parapertussis. Because B. 
parapertussis Xwbm is not defective in colonization of mice 
lacking complement (11), sera were generated in complement­
deficient mice, thereby removing the difference in bacterial 
load as a factor affecting antibody production. Compared to 
the naive sera, B. parapertussis immune sera mediated efficient 
opsonization of wild-type B. parapertussis and subsequent at­
tachment to and phagocytosis by PMNs (Fig. 5, middle black 
bars). B. parapertussis immune sera were less effective against 
O-antigen-deficient B. parapertussis in all three assays (Fig. 5, 
middle white bars), suggesting that antibodies recognizing the 
O antigen, rather than the shared antigens, are involved. Sera 
from mice immunized with O-antigen-deficient B. parapertus­
sis were similarly effective against the wild-type and O- 
antigen-deficient strains (Fig. 5, right). Control PMNs 
treated with cytochalasin, a phagocytosis inhibitor, showed 
no phagocytosis (data not shown), indicating that although 
indirect, the assay measured phagocytosis. The observed 
high levels of activity of B. parapertussis immune sera against 
wild-type but not O-antigen-deficient B. parapertussis sug­
gest that much of this activity is mediated by antibodies to 
the O antigen.
The O antigen is required for the generation of antibodies 
that efficiently clear B. parapertussis. To determine if the de­
creased B. parapertussis-specific antibody titers of, and op­
sonophagocytosis mediated by, sera raised against B. paraper­
tussis Awhm result in decreased antibody-mediated clearance 
in vivo, mice received passively transferred naive sera or sera 
raised against wild-type or O-antigen-deficient B. parapertussis 
in C3 mice. Mice were then challenged with B. parapertussis 
and sacrificed on day 14 postchallenge for bacterial enumera­
tion, since B. parapertussis poorly stimulates Toll-like receptor 
4 (TLR4) and antibodies therefore have no effect until around 
day 14 after T cells have been generated (19, 55; D. N. Wolfe, 
unpublished data). Naive sera had no effect on bacterial 
loads throughout the respiratory tract on day 14 postchal­
lenge (Fig. 6). As seen in previous studies (19, 56), B. para­
pertussis immune sera decreased the bacterial loads in the 
trachea and lungs by 96 and 99.6% at this time point. How­
ever, B. parapertussis Awhm immune sera failed to signifi­
cantly reduce B. parapertussis colonization, indicating that 
the O antigen is required for the generation of antibodies 
that clear B. parapertussis from the LRT in vivo upon adop­
tive transfer. Neither serum treatment affected bacterial 
numbers in the nasal cavity.
Supplementing Adacel with B. parapertussis LPS containing 
the O antigen confers protection against B. parapertussis chal­
lenge. Since the O antigen is necessary for the generation of
FIG. 5. Generation of antibodies that mediate efficient opsono­
phagocytosis of B. parapertussis by PMNs requires the O antigen. 
GFP-expressing wild-type B. parapertussis (Bpp) or O-antigen-deficient 
B. parapertussis (Bppbwbm) was opsonized with naïve sera or sera from 
(3 mice challenged with B. parapertussis (B. parapertussis immune 
sera [B.p.p. IS]) or B. parapertussis Awbm (B.p.p.lswbm IS) and stained 
with RPE-labeled goat F(ab')2 fragments of anti-mouse IgG. (A) Op­
sonization levels were measured as mean intensities ± standard errors 
of red fluorescence from bacteria opsonized with the indicated sera 
from four individual mice. (B) Opsonized bacteria were incubated with 
freshly isolated human peripheral blood PMNs for 20 min or 1 h and 
20 min. Attachment levels were measured as mean intensities ± stan­
dard errors of green fluorescence associated with PMNs incubated for 
20 min with bacteria opsonized by the indicated sera from four indi­
vidual mice. (C) The cell surface-bound bacteria on PMNs were de­
tected by incubation with RPE-labeled goat F(ab')2 fragments of anti­
mouse IgG. Mean phagocytosis levels ± standard errors were 
calculated from the drop in red fluorescence of green fluorescence­
positive cells incubated for 1 h and 20 min compared to that of cells 
incubated for 20 min. Results were obtained from experiments done 
with four independent serum samples. AU indicates arbitrary units; * 
indicates a P value of u0.05; ** indicates a P value of <0.01.
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efficient protective immunity to B. parapertussis (Fig. 1, 2, and 
4), we examined whether B. parapertussis LPS alone, contain­
ing the O antigen, is sufficient to induce protective immunity 
against this pathogen and whether supplementing Adacel with 
B. parapertussis LPS renders this vaccine effective against B. 
parapertussis. Mice were vaccinated with an adjuvant alone, the 
acellular pertussis vaccine Adacel with an adjuvant, or Adacel 
with an adjuvant supplemented with purified LPS from B. 
parapertussis or B. parapertussis Awhm. Vaccination with adju-
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FIG. 6. Antibodies to the O antigen are required for efficient an­
tibody-mediated clearance of B. parapertussis. Groups of four C57BL/6 
mice were inoculated with B. parapertussis and i.p. injected with the 
indicated serum. Bacterial loads in the nasal cavities, tracheae, and 
lungs at 14 days postinoculation are expressed as the log10 means ± 
standard errors. * indicates a P value of £0.05 for comparison between 
results for groups receiving naive serum (NS) and B. parapertussis 
immune serum. $ indicates a P value of £0.05 for comparison between 
results for groups receiving B. parapertussis Swbm immune serum 
(B.p.p. Swbm IS) and wild-type B. parapertussis immune serum (B.p.p. 
IS). The limit of detection is indicated by the y axis.
vant alone or Adacel had no effect on B. parapertussis loads 
throughout the respiratory tract 3 days postchallenge (Fig. 
7A). In contrast, vaccination with B. parapertussis LPS, but not 
B. parapertussis ISwbm LPS, significantly reduced B. paraper­
tussis loads in the lungs by 93.8% compared to those in the 
group vaccinated with adjuvant alone. Moreover, the addition 
of B. parapertussis LPS, but not B. parapertussis ¿M’bm LPS, to 
Adacel caused significant decreases in bacterial loads, by 70.7, 
99.6, and 96.2% in the nasal cavity, trachea, and lungs, respec­
tively, suggesting that the efficacy of an acellular pertussis vac­
cine against B. parapertussis may be increased if B. parapertussis 
LPS containing the O antigen is included. To ensure that the 
addition of B. parapertussis LPS did not have an impact on the 
efficacy of Adacel against B. pertussis, mice were immunized 
with this vaccine with or without B. parapertussis LPS and 
challenged with B. pertussis. As expected, vaccination with the 
adjuvant alone did not affect the colonization by B. pertussis 
compared to that of naive animals (Fig. 7B). Vaccination with 
Adacel reduced the B. pertussis load in the lungs by >99.5% 
(Fig. 7B, bottom). This vaccine supplemented with B. para­
pertussis LPS caused a similar reduction of B. pertussis numbers 
(Fig. 7B, bottom), suggesting that the inclusion of B. paraper­
tussis LPS does not affect the efficacy of the vaccine against B. 
pertussis. All together, our data suggest that the addition of B. 
parapertussis LPS containing the O antigen to a current acel­
lular vaccine extended its utility to include protective immunity 
to B. parapertussis.
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FIG. 7. Addition of purified B. parapertussis LPS to an acellular B. pertussis vaccine confers protection against B. parapertussis challenge. Groups 
of four C57BL/6 mice were vaccinated as indicated and then challenged with B. parapertussis (B.p.p.) (A) or B. pertussis (B.p.) (B) and dissected 
at day 3 postchallenge. The numbers of CFU recovered from the nasal cavities, tracheae, and lungs are expressed as the log10 means ± the standard 
errors. ND indicates that CFU were not detectable. * indicates a P value of £0.05. The limit of detection is indicated by the y axis.
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DISCUSSION
A clear picture of B. parapertussis epidemiology is not avail­
able because differential diagnostic methods to distinguish the 
two causative agents of whooping cough are rarely performed 
at the clinical level and diseases caused by B. parapertussis are 
not reportable to the CDC. However, when carefully moni­
tored, B. parapertussis has been found to cause a substantial 
proportion of whooping cough cases and even larger propor­
tions among vaccinated groups (4, 23, 24, 50). Although the 
mouse model does not replicate coughing symptoms of the 
disease, mechanisms of immune control and clearance of 
the bordetellae are consistent with what is known of these 
mechanisms in humans (19, 29, 30). The data presented here 
are consistent with the findings of experimental studies using a 
mouse infection model, as well as those of clinical studies, in 
which B. pertussis immunity failed to induce protective immu­
nity to B. parapertussis (Fig. 7A) (9, 10, 14, 23, 27, 52, 56, 59). 
This work extends the findings of those previous studies to 
examine the role of the O antigen in the generation of B. 
parapertussis-specific immunity.
We found that although immunization with wild-type B. 
parapertussis induced protective immunity to both the wild­
type and the O-antigen-deficient B. parapertussis strains, prior 
infection or vaccination with the O-antigen-deficient strain 
conferred significantly less protection against the wild type in 
the lungs (Fig. 1 and 2). Immunization with B. parapertussis 
¿Swbm induced splenic cytokine production similar to that in­
duced by wild-type vaccination (Fig. 3), indicating that the 
decrease in protection conferred by the O-antigen-deficient 
strain was not due to inefficient T-cell cytokine production. 
Interestingly, B. parapertussis-induced antibodies recognized 
the O antigen as a dominant antigen (Fig. 4A and B, lanes 3 
and 4). Serum antibodies raised against the wild type, but not 
the O-antigen-deficient strain, mediated efficient opsono- 
phagocytosis and reduced B. parapertussis colonization upon 
passive transfer (Fig. 5). Together, these data suggest that the 
O antigen is required for the generation of an effective anti­
body response against B. parapertussis.
Antibodies raised against B. parapertussis Awhm lacked rec­
ognition of the O antigen but recognized different antigens 
from those recognized by antibodies raised against wild-type B. 
parapertussis (Fig. 4B) and efficiently cleared B. parapertussis 
¿Swbm (Fig. 1). These antigens are present in the B. paraper­
tussis lysate (Fig. 4B), but B. parapertussis Awbm immune se­
rum is much less effective at binding live bacteria, mediating 
opsonophagocytosis in vitro, or mediating bacterial clearance 
in vivo than B. parapertussis immune serum (Fig. 4 to 6), sug­
gesting that these antigens may not be recognized on the sur­
faces of live B. parapertussis cells expressing the O antigen. 
These data further indicate that the O antigen is a dominant 
surface antigen of B. parapertussis and that antibodies against 
it are required for efficient clearance of this bacterium.
The O antigen seems to contribute to the generation of 
effective protective immunity against B. parapertussis in the 
lungs but not in the trachea or nasal cavity (Fig. 1 and 2). 
Wolfe et al. observed that B cells and T cells are required for 
clearance of B. parapertussis from the lungs and that CD4 T 
cells, complement, and neutrophils are required for antibody- 
mediated clearance in this organ (58). What immune compo­
nents are required for B. parapertussis clearance in the trachea 
and nasal cavity is less understood. Infection-induced immu­
nity appeared to be more effective than vaccination-induced 
immunity in the nasal cavity and trachea (Fig. 1 and 2). This 
pattern may be due to different clearance mechanisms in in­
fection- and vaccination-induced immunity to bordetellae (12). 
Vaccination is efficient in controlling disease but may be less 
effective in preventing subclinical colonization, as observed 
with B. pertussis (28). While the nasal cavity may be a reservoir 
of asymptomatic carriage of B. parapertussis, the protection in 
the lungs correlates with vaccine efficacy against severe disease 
and is thus the focus of this study (9).
The incidence of whooping cough has increased over the 
past 20 years, despite the maintenance of excellent vaccine 
coverage in developed countries (5). This trend may be due, at 
least in part, to vaccines’ being ineffective against B. paraper­
tussis-induced disease (9, 16, 23). Of note, the switch from 
whole-cell to acellular vaccines correlates with increased prev­
alence of B. parapertussis (23). Moreover, whooping cough 
vaccinations have been proposed to shape the age-incidence 
patterns of the two causative agents. B. pertussis is more com­
mon in infants prior to vaccination and adolescents in whom 
vaccine-induced immunity has waned (6, 53), whereas B. 
parapertussis is most common in young children who have been 
recently vaccinated (3, 21, 54; J. Lavine, L. Han, E. T. Harvill, 
and O. Bjornstad, unpublished data). All these observations 
suggest that current whooping cough vaccines confer a selec­
tive advantage on B. parapertussis in its ongoing competition 
with B. pertussis.
We have shown that supplementing the acellular pertussis 
vaccine Adacel with 10 p.g of purified B. parapertussis LPS 
containing the O antigen reduced B. parapertussis numbers in 
the LRT by more than 90% within 3 days compared to the 
numbers in the group receiving Adacel alone (Fig. 7). Thus, 
the addition of this single antigen increased the efficacy of this 
vaccine against B. parapertussis in the mouse model. These 
results are not necessarily easily translated to improved human 
vaccines, since vaccine reactogenicity has been associated with 
LPS of B. pertussis. However, B. parapertussis LPS is less stim­
ulatory toward TLR4 than B. pertussis LPS, and it is possible to 
purify the O antigen portion of the LPS (20, 26, 55), thereby 
removing the TLR4 agonist, lipid A, to which is attributed 
most of the proinflammatory stimulation (32). Alternatively, 
other, as-yet-unidentified antigens of B. parapertussis may 
prove to be protective and could be added to acellular whoop­
ing cough vaccines. However, the poor protection conferred by 
the O-antigen-deficient strain and the ability of the O antigen 
to block the effects of antibodies recognizing other antigens 
(56, 59) suggest that the inclusion of the O antigen in the 
whooping cough vaccines should be favored over other, as-yet- 
unidentified protein antigens.
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